Sort
15,842 grants matching “pancreatic cancer”
Advancing Systematic Delivery of Oncolytic Adenovirus for Pancreatic Cancer
$480,793Julia Davydova · University Of Minnesota · R01 · FY2023 · CA
Co-targeting BET Bromodomain Proteins and MNK Kinases in Pancreatic Cancer
$480,703Hidayatullah G Munshi · Northwestern University At Chicago · R01 · FY2023 · CA
Transcriptomic origins of cancer
$480,697Sridhar Hannenhalli · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
$480,634James K Turkson · University Of Hawaii At Manoa · R01 · FY2016 · CA
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
$480,634James K Turkson · University Of Hawaii At Manoa · R01 · FY2015 · CA
Next-Generation Antibody Discovery and Development Technology
$480,577David Scott Johnson · Gigagen, Inc. · R44 · FY2017 · CA
Machine learning accelerated on-line adaptive replanning
$480,490Eric S Paulson · Medical College Of Wisconsin · R01 · FY2022 · CA
Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy
$480,479Ruiwen Zhang · Texas Tech University Health Scis Center · R01 · FY2016 · CA
Development of Methods for Cancer Biomarker Detection
$480,464Wistar Institute · R33 · FY2003 · CA
Elucidation of hypoxia-induced metastatic reprogramming through the regulation of KDM8 function in pancreatic cancer
$480,423Shin-Heng Chiou · Rutgers Biomedical And Health Sciences · R01 · FY2024 · CA
Functions of the LKB1 tumor suppressor in control in metabolism and epigenetics
$480,226Nabeel Bardeesy · Massachusetts General Hospital · R01 · FY2020 · CA
The development of Saccharomyces (yeast) vaccines for cancer therapy
$480,181James Hodge · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Uncovering Oncogenotype-specific Vulnerabilities in Lung cancer
$480,137Jiyeon Kim · Yale University · R37 · FY2024 · CA
Palliative Care: Maximizing Patient Preference
$480,056Donald H Taylor · Duke University · R01 · FY2011 · HS
DYSBIOTIC MICROBIOME IN PANCREATITIS, DIABETES, AND PANCREATIC CANCER
$480,038William E Fisher · Baylor College Of Medicine · U01 · FY2021 · DK
The Development And Progression Of IPMN To PDA In The Context Of Inactivated Activin Signaling
$480,016Gloria Huei-Ting Su · Columbia University Health Sciences · R01 · FY2021 · CA
DYSBIOTIC MICROBIOME IN PANCREATITIS, DIABETES, AND PANCREATIC CANCER
$480,000William E Fisher · Baylor College Of Medicine · U01 · FY2022 · DK
Phase I/II clinical evaluation of ABTL0812, a novel PI3K/Akt/mTOR inhibitor, with a unique mechanism of action inpancreatic cancer (Protocol sent on 20th June 2019 as an amendment of the IND 137394)
$480,000Davendra Sohal · University Of Cincinnati · R01 · FY2022 · FD
DYSBIOTIC MICROBIOME IN PANCREATITIS, DIABETES, AND PANCREATIC CANCER
$480,000William E Fisher · Baylor College Of Medicine · U01 · FY2023 · DK
DYSBIOTIC MICROBIOME IN PANCREATITIS, DIABETES, AND PANCREATIC CANCER
$480,000William E Fisher · Baylor College Of Medicine · U01 · FY2020 · DK
Impact of RB activation on the pancreatic cancer epigenome and tumor microenvironment
$479,955Agnieszka Witkiewicz · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA
Elucidation of hypoxia-induced metastatic reprogramming through the regulation of KDM8 function in pancreatic cancer
$479,942Shin-Heng Chiou · Rutgers Biomedical And Health Sciences · R01 · FY2025 · CA
Disposable Perfusion Phantom for Accurate DCE-MRI Measurement of Pancreatic Cancer Therapy Response
$479,816Harrison Kim · University Of Alabama At Birmingham · UH3 · FY2022 · CA
Combined radiation acoustics and ultrasound imaging for real-time guidance in radiotherapy
$479,760Issam M. El Naqa · H. Lee Moffitt Cancer Ctr & Res Inst · R37 · FY2023 · CA
Targeting the RNA Exosome for Cancer Therapeutics
$479,616Mats Ljungman · University Of Michigan At Ann Arbor · R01 · FY2023 · CA